NCT00682292View on ClinicalTrials.gov

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

PHASE3CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Renal Transplantation
Interventions
DRUG

Thymoglobulin (ATG)

Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation

DRUG

Daclizumab

Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation

Trial Locations (1)

59037

University Hospital of Lille, Lille

All Listed Sponsors
collaborator

Erasme University Hospital

OTHER

lead

University Hospital, Lille

OTHER

NCT00682292 - Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk | Biotech Hunter | Biotech Hunter